LAM) ('a) A statement is enclosed.

(b) a foreign colla boration, have been approved for the manufacture of scooter| moped. All units are required to submit their monthly production report to the Government.

statement

A. *Passenger Cars* :

	Name of the Indian Company	Name of the Collaborator	Nature
1	Maruti Udyog Limited, Gurgaon	Suzuki Motors Company, Japan	Technical and Financial.
2	Premier Automobiles Limited Bombay	Nissan Motor Company, Japan	Technical (Engine-Transmission only).
3	Hindustan Motors Limited Calcutta	Isuzu Motor Company, Japan	Tech. (Engine-Transmission only).
4	Standard Motor Products of India Limited, Madras.	Austin Rover, U.K.	Technical.
5	Sipani Automobiles Limited, Madras	Reliant Motor Company, U.K.	Technical (Engine only).

Indian Drugs and Pharmaceuticals Limited

1507. SHRI MAHENDRA MOHAN MISHRA: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news which appeared in Financial Express on 29th January, 1986 under the heading "IDPL may turn corner by next •year";

(b) what are the details of rehabilitation plan in regard to updating the technology of Erythromycin, Potassium Penicillin. Griseofulvin, Tetracycline, Oxytetra-cycline, Streptomycin, Doxycycline, Me-thyldopa, Chloroquin Phosphate and Vitamin B-6 being produced by IDPL;

(c) whether IDPL purchased technology for the production of these drugs, if so, the name of the party from whom it was purchased and what was the procedure of payment in each case;

(d) what was the technical know-how fee paid for each drug and how much investment was made on plant and machinery for the production of each drug; and

(e) what was the production of each drug during the last three years, yearwise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) In-house task force was constituted in December, 1985 by IDPL to identify the constraints and opportunities and to come out with concrete plans for rehabilitation and revival including up-dating the technology of these drugs. In order to catalyse the functioning of the task force and to provide it the necessary analytical expertise two consultants were associated by the company with the task force on part-time basis. The task force has not yet completed its studies.

(c) and (d) Details regarding the name of the party from whom each of these drug was purchased, know-how fee paid, and the value of plant and machinery are given in the attached Statement-I. Know-how fees for imported technology was required to be paid in instalments. The last instalment was required to be made after satisfactory performance of trials within the time stipulated in the agreement.

(e) Details of production in respect of each of these drugs during the last three years are given in the attached State-ment-II.

Statement-I

Indian Drugs and Pharmaceuticals Limited

Name of the product	Technical know-how fee paid	Source	Investment (Gross block) in Plant & Machinery as on 31-3-1985
Erythromycin Estolate US	$ 6,68,460	M/s Farmafin, Italy	Rs. 205·48 lakhs
Pot Penicillin US	$ 4,00,000	Do.	Rs. 445·11 ,,
Tetracyline HCl. US	$ 2,83,920	Do.	Rs. 331 78 ,,
Doxycycline Phyclate US	$ 1,22,000	Do.	Rs. 115·02 ,,
Griseagfulvin	No separate technical know how fee paid. It was obtained as a part of collaboration arrangement.	USSR technology	Rs. 9·59 ,,
Oxytetracycline			Rs. 42·49 ,,
Stretomycin			Rs. 222·43 ,,
Methtyldopa .	—	Own technology	Rs. 17·39 ,,
Chloroquin Phosphate .	—	Do.	Rs. 112·52 ,,
Vitamin B6 . . .	—	Do.	Rs. 200·25 ,,

Statement-II

Indian Drugs and Pharmaceuticals Limited

Production Performance during the year 1982-83, 1983-84 *and* 1984-85

Sl. No.	Item	Unit	1982-83	1983-84	1984-85
1	Erythromycin S	MT	..	0.20	..
	E	,,		0.90	..
2	Pot. Penicillin G	MMU	92.70	123.00	129.50
3	Griseofulvin	MT	..	..	..
4	Tetracycline	MT	126.89	115.20	121.30
5	Oxytetracycline	MT	49.72	20.50	49.20
6	Strepto-Sulphate	T/base	40.19	35.80	27.10
7	Chloroquine Phos.	MT	..	..	0.25
8	Methyldopa	MT	0.18	1.30	3.27
9	Doxycycline	MT	0.01	..	..
10	Vitamin B6	MT	..	0.995	1.17